PHVS
NASDAQ
$33.55
Pharvaris NV (PHVS)
Pharvaris NV, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of rare disease therapies. The company is headquartered in Leiden, the Netherlands.
Sector:
Healthcare
Industry:
Biotechnology
Buy
Target: $47.27 (+40.89%)
Market Cap
$2.30B
FCF 5Y CAGR
+37.90%
Free Cash Flow Yield
-7.55%
Beta (5Y)
0.66
Price Chart
Valuation
Market Cap$2.30B
P/B8.94
Profitability
EBITDA-$141M
EPS-$3.23
Financial Health
Debt-to-Equity0.3%
Free Cash Flow Yield-7.55%
Growth & Risk
EPS 5Y CAGR+9.20%
FCF 5Y CAGR+37.90%
Beta (5Y)0.66
Sharpe Ratio0.82